Government-Owned Inventions; Availability for Licensing, 40775-40776 [2017-18137]

Download as PDF 40775 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices There will be a final report that is thematically organized and describes key findings and strategic recommendations for Region VIII OASH/OWH to consider supporting future evidence-based program development and implementation, policy recommendations, and future research. Likely Respondents: Data for this assessment will be collected through three mechanisms—a survey of women living in the assessment geography, focus groups with a cross-section of women and other key groups living in the assessment geography, key leaders and stakeholders across a variety of governmental and non-governmental sectors. The total annual burden hours estimated for this ICR are summarized in the table below. TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Number of respondents Form name Number of responses per respondent Average burden per response (in hours) Total burden hours Community Survey .......................................................................................... Focus Groups .................................................................................................. Interviews ......................................................................................................... 500 240 40 1 1 1 15/60 90/60 60/60 125 360 40 Total .......................................................................................................... 780 1 40.4/60 525 (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Terry S. Clark, Asst Information Collection Clearance Officer. [FR Doc. 2017–18117 Filed 8–25–17; 8:45 am] BILLING CODE 4150–33–P Dated: August 22, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2017–18121 Filed 8–25–17; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting asabaliauskas on DSKBBXCHB2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Peer Review Meeting. Date: September 20–21, 2017. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program, Division of Extramural Activities, Room 3F40B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5036, poeky@mail.nih.gov. VerDate Sep<11>2014 18:45 Aug 25, 2017 Jkt 241001 National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240–627–3705, Chris.Kornak@nih.gov. Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. SUMMARY: PO 00000 Frm 00032 Fmt 4703 HIV Targets CD62L on Central Memory T Cells Through Viral Envelope Glycans for Adhesion and Induces Selectin Shedding for Viral Release Description of Technology DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Sfmt 4703 Despite the success of anti-retroviral therapy in controlling HIV in infected individuals, treatment is less effective at eliminating HIV viral reservoirs. The nature of HIV reservoirs and the factors controlling their size and release are a major research focus for achieving a cure for HIV/AIDS. NIAID researchers have identified Lselectin/CD62L as a new target for treating HIV by inhibiting viral release from infected cells. They found that shedding of CD62L on T cells is required for the efficient release of HIV virus from infected cells. Further, they have shown that inhibition of CD62L shedding dramatically reduced HIV–1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • New target for HIV therapeutic development. E:\FR\FM\28AUN1.SGM 28AUN1 40776 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices Competitive Advantages • This invention comprises a method of treating HIV using therapeutics geared toward viral release and entry, distinguishing it from other antiviral candidates with its method of action. • CD62L is a new target for HIV Development Stage • In vitro studies; Proof-of-concept studies. Inventors Peter Sun, NIAID, NIH Joseph Kononchik, NIAID, NIH Joanna Ireland, NIAID, NIH Ruiping Wang, NIAID, NIH Intellectual Property: HHS Reference No. E–261–2015/0—PCT No. PCT/ US2016/068713 filed 12/27/2016. Licensing Contact: Chris Kornak, 240– 627–3705, Chris.Kornak@nih.gov. Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further codevelop this technology by identifying pharmacological compounds inhibiting CD62L shedding by using high throughput compound screening. For collaboration opportunities, please contact Chris Kornak, 240–627–3705, Chris.Kornak@nih.gov. Dated: August 15, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–18137 Filed 8–25–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health asabaliauskas on DSKBBXCHB2PROD with NOTICES Office of the Director; Notice of Charter Renewal It is determined that the Advisory Committee to the Deputy Director for Intramural Research, National Institutes of Health, is in the public interest in connection with the performance of duties imposed on the National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group. In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the Charter for the Advisory Committee to the Deputy Director for Intramural Research, National Institutes of Health, was renewed for an VerDate Sep<11>2014 18:45 Aug 25, 2017 Jkt 241001 additional two-year period on August 15, 2017. Inquiries may be directed to Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496– 2123, or spaethj@od.nih.gov. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: August 18, 2017. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. AGENCY: [FR Doc. 2017–18197 Filed 8–25–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Initial Review Group; Behavior and Social Science of Aging Review Committee. Date: October 5–6, 2017. Time: 3:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Kimberly Firth, Ph.D., National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7702, kimberly.firth@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: August 23, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–18199 Filed 8–25–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 National Institutes of Health Proposed Collection: 60-Day Comment Request; Generic Clearance To Support the Safe to Sleep® Campaign at the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) National Institutes of Health, HHS. ACTION: Notice. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Lorena Kaplan, M.P.H., CHES, Office of Communications, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, Room 2A32, Bethesda, Maryland 20892, or call non-toll free number (301) 496–6670 or Email your request, including your address to lorena.kaplan@nih.gov. Formal requests for additional plans and instruments must be requested in writing. SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be SUMMARY: E:\FR\FM\28AUN1.SGM 28AUN1

Agencies

[Federal Register Volume 82, Number 165 (Monday, August 28, 2017)]
[Notices]
[Pages 40775-40776]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18137]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
Chris.Kornak@nih.gov. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

HIV Targets CD62L on Central Memory T Cells Through Viral Envelope 
Glycans for Adhesion and Induces Selectin Shedding for Viral Release

Description of Technology

    Despite the success of anti-retroviral therapy in controlling HIV 
in infected individuals, treatment is less effective at eliminating HIV 
viral reservoirs. The nature of HIV reservoirs and the factors 
controlling their size and release are a major research focus for 
achieving a cure for HIV/AIDS.
    NIAID researchers have identified L-selectin/CD62L as a new target 
for treating HIV by inhibiting viral release from infected cells. They 
found that shedding of CD62L on T cells is required for the efficient 
release of HIV virus from infected cells. Further, they have shown that 
inhibition of CD62L shedding dramatically reduced HIV-1 infection and 
viral release from both viremic and aviremic CD4+ T cells. Therefore, 
inhibitors for CD62L sheddase can function as an anti-HIV treatment 
that may be effective alone or in combination with existing 
therapeutics.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     New target for HIV therapeutic development.

[[Page 40776]]

Competitive Advantages

     This invention comprises a method of treating HIV using 
therapeutics geared toward viral release and entry, distinguishing it 
from other antiviral candidates with its method of action.
     CD62L is a new target for HIV

Development Stage

     In vitro studies; Proof-of-concept studies.

Inventors

Peter Sun, NIAID, NIH
Joseph Kononchik, NIAID, NIH
Joanna Ireland, NIAID, NIH
Ruiping Wang, NIAID, NIH

    Intellectual Property: HHS Reference No. E-261-2015/0--PCT No. PCT/
US2016/068713 filed 12/27/2016.
    Licensing Contact: Chris Kornak, 240-627-3705, 
Chris.Kornak@nih.gov.
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology by 
identifying pharmacological compounds inhibiting CD62L shedding by 
using high throughput compound screening. For collaboration 
opportunities, please contact Chris Kornak, 240-627-3705, 
Chris.Kornak@nih.gov.

    Dated: August 15, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-18137 Filed 8-25-17; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.